This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Celestica (CLS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Celestica (CLS) delivered earnings and revenue surprises of 4.76% and 0.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Celestica (CLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Celestica (CLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy Celestica (CLS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Celestica (CLS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PagerDuty (PD) Q4 Loss Narrower Than Expected, Revenues Rise
by Zacks Equity Research
PagerDuty's (PD) fourth-quarter fiscal 2021 results reflect an expanded partner base and new customer wins.
Plexus (PLXS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Plexus (PLXS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Jabil (JBL) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Jabil's (JBL) second-quarter fiscal 2021 results reflect benefits from contract wins in healthcare, automotive, connected devices, cloud and 5G. Steady revenue growth in the DMS segment is observed.
Is Celestica (CLS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Celestica (CLS) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Celestica (CLS) has been struggling lately, but the selling pressure may be coming to an end soon
Plexus (PLXS) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Plexus (PLXS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Investors Undervaluing Celestica (CLS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Top Ranked Growth Stocks to Buy for February 18th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 18th
5 Low Price-to-Book Stocks for Value Investors
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Should Value Investors Consider Celestica (CLS) Stock Now?
by Zacks Equity Research
Let's see if Celestica (CLS) stock is a good choice for value-oriented investors right now from multiple angles.
Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals
Pick These 4 Low P/CF Stocks for a Value-Based Portfolio
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Sanmina Corporation (SANM), Canadian Solar (CSIQ), Celestica (CLS) and Alexion Pharmaceuticals (ALXN) boast low P/CF ratio.
Top Ranked Growth Stocks to Buy for February 12th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 12th
Top Ranked Growth Stocks to Buy for February 9th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 9th
Top Ranked Growth Stocks to Buy for February 5th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, February 5th
Are Investors Undervaluing Celestica (CLS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Celestica (CLS) Q4 Earnings Top Estimates
by Zacks Equity Research
Celestica (CLS) delivered earnings and revenue surprises of 4.00% and -1.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Amkor, Celestica, Big Lots, Cowen and Regal Beloit
by Zacks Equity Research
Zacks.com featured highlights include: Amkor, Celestica, Big Lots, Cowen and Regal Beloit
Is Celestica (CLS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Value Stocks With Impressive EV-to-EBITDA Ratios to Own Now
by Zacks Equity Research
We have screened value stocks Amkor (AMKR), Celestica (CLS), Big Lots (BIG), Cowen (COWN) and Regal Beloit (RBC) based on EV-to-EBITDA ratio that offers a clearer picture of a company's valuation and earnings potential.
Celestica (CLS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Celestica (CLS) delivered earnings and revenue surprises of 33.33% and 3.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?